Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16682126 | 0.91 | HPGD (0.42) | CDK2CCNE1MAPK1NPY5RACKR3 | |
| SCHEMBL16675916 | 0.87 | CDK2 (0.48) | CDK2CCNE1MAPK1GSK3BPOLB | |
| SCHEMBL16682080 | 0.86 | CCNE1 (0.37) | CDK2CCNE1MAPK1POLB | |
| SCHEMBL18556907 | 0.85 | CCNE1 (0.37) | CDK2CCNE1MAPK1POLB | |
| SCHEMBL16682110 | 0.83 | MAPK1 (0.36) | CDK2CCNE1MAPK1POLB | |
| SCHEMBL18558426 | 0.81 | MAPK1 (0.37) | MAPK1 | |
| SCHEMBL18558119 | 0.81 | MAPK1 (0.38) | CDK2CCNE1MAPK1 | |
| SCHEMBL18556902 | 0.80 | CCNE1 (0.39) | CDK2CCNE1MAPK1ACKR3 | |
| SCHEMBL18558551 | 0.80 | ALDH1A1 (0.41) | CDK2CCNE1MAPK1POLBNPY5R | |
| SCHEMBL18558522 | 0.80 | SMN1; SMN2 (0.41) | CDK2POLBCCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | CDK2 3048/4885CCNE1 3962/4885MAPK1 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.